Riad Sherif & Oculis

Riad Sherif: Riad Sherif, as CEO of Oculis, is the presenter of the Privosegtor program, emphasizing the company's strategic direction and the potential of the drug.

Oculis: Oculis is presenting its Privosegtor program at a major clinical trials summit, highlighting its progress in developing a potential neuroprotective therapy for optic neuritis, which could significantly benefit the company.

Riad Sherif: As CEO of Oculis, Riad Sherif announced the disappointing Phase 3 trial results for OCS-01 and outlined the company's strategic shift to focus on other late-stage development programs.

Oculis: Oculis announced that its OCS-01 eye drops failed to meet the primary endpoint in Phase 3 trials for diabetic macular edema (DME), leading to a decision not to pursue FDA regulatory filing for this indication. This negatively impacts Oculis's stock and future revenue expectations for OCS-01 in DME.

Riad Sherif: Dr. Riad Sherif, CEO of Oculis, will be the presenter at the fireside chat, representing the company.

Oculis: Oculis will present its late-stage portfolio and pipeline updates at the conference, potentially increasing investor interest and its stock value.